344
Productivity & Workflow355
Automation & Workflow224
Software Development251
Marketing & Growth192
AI Infrastructure & MLOps174
Writing & Content Creation203
Data & Analytics141
Photography & Imaging156
Design & Creative170
Customer Support132
Sales & Outreach125
Voice & Speech135
Education & Learning131
Operations & Admin87
Tech entrepreneur Bryan Johnson is publicizing Blueprint, a daily regimen with heavy health tracking, supplements, and tests aimed at lowering his biological age.
In short: Bryan Johnson is drawing attention to Blueprint, his public longevity project that uses strict routines and constant health measurement to try to slow biological aging.
Bryan Johnson, a tech entrepreneur, has made “don’t die” the slogan for a project called Blueprint. The project is built around tight control of daily life and frequent testing. He says the goal is to slow, and possibly reverse, signs of aging in his body.
A key idea in Blueprint is “biological age,” which means how old your body seems based on health signals, not how many birthdays you have had. Johnson also talks about “age escape velocity,” meaning a future point where one calendar year passes but his biological age does not go up. Think of it like trying to keep a car’s mileage from increasing by constantly swapping parts and tuning the engine (except the “car” is the human body).
Reporting on his routine says it is expensive. Some outlets have cited more than $4 million spent overall, and others describe spending around $2 million per year.
Blueprint, as described across coverage, includes large amounts of supplements, including reports of 111 pills a day. It also includes a tightly controlled diet, sleep schedule, and exercise routine. It relies on frequent tests of “biomarkers,” meaning measurable health signs like blood results and organ level readings.
Some reports also mention advanced or experimental steps, such as red light therapy, hyperbaric oxygen therapy (breathing oxygen in a high pressure chamber), and plasma transfusions.
Johnson is not presenting Blueprint as only a personal experiment. He is also selling it as a public protocol and brand. The big question is whether his measured results will hold up outside his own case, and whether more independent research will confirm the benefits and risks.
Source: NYTimes